Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.



Gasdermin D (GSDMD) as a new target for the treatment of infection

Author affiliations

Abstract

The discovery of a previously unknown protein, gasdermin D (GSDMD), as the key effector that leads to pyroptosis and NETosis has created much excitement. Since its initial report in Oct. 2015, more than 200 papers have been published on studies of the structure and mechanism of GSDMD and its homologues. The clear connection between infection and inflammasome activation made GSDMD a promising target for the development of anti-infection treatment. In this mini review, we discuss first the current understanding of the structure and mechanism of GSDMD, focusing on its potential as a druggable target, and then recent efforts in the development of inhibitors to interfere with the pore-forming function of GSDMD and thus alleviate the detrimental effects due to pyroptotic cell death.

Graphical abstract: Gasdermin D (GSDMD) as a new target for the treatment of infection

Back to tab navigation

Publication details

The article was received on 31 Jan 2019, accepted on 04 Apr 2019 and first published on 04 Apr 2019


Article type: Review Article
DOI: 10.1039/C9MD00059C
Med. Chem. Commun., 2019, Advance Article

  •   Request permissions

    Gasdermin D (GSDMD) as a new target for the treatment of infection

    A. Pandeya, L. Li, Z. Li and Y. Wei, Med. Chem. Commun., 2019, Advance Article , DOI: 10.1039/C9MD00059C

Search articles by author

Spotlight

Advertisements